bioRxiv Science⌕ Search

Biology subjects

Atti, S.

Publications and source records attributed to Atti, S..

2 recordsLinked to original sources

Fundamental Limitations of Foundation Models in Single-Cell Transcriptomics

Recent applications of foundation models in biology have focused on pretraining using large-scale single-cell datasets comprising millions of cells, across diverse patho-physiological states. These models are then fine-tuned for downstream tasks such as cell-type classification. In this study, we evaluated the performance of three widely-used foundation models in biology--scGPT, SCMAMBA-2, and Geneformer--and a statistical baseline (Seurat v5) on cell-type classification under Gaussian noise perturbation. We used two curated datasets, referred to as Myeloid (13k cells) and hPancreas (15k cells). Surprisingly, we found that the baseline performance of the foundation models was inferior to that of the statistical model, even without any added perturbation. Although we note that model size can affect performance, Geneformers accuracy outperformed scGPT and SCMAMBA-2 by 5% on average across all datasets despite having 40% fewer trainable parameters. Nonetheless, the statistical baseline still outperformed Geneformer by 9% in accuracy. Based on these findings, we hypothesized that the conventional training paradigm used by foundation models for single-cell tasks consistently underperforms statistical models due to a lack of essential biological context. To investigate this, we evaluated whether performance degradation stems from early data embedding steps--such as binning or gene normalization during tokenization, and sampling bias. First, to better understand tokenization-related artifacts, we introduced controlled Gaussian noise to gene expression values before tokenization, amplifying downstream distortions introduced by the tokenization process (all models were trained for identical step durations with identical hyperparameters). On the Myeloid dataset, following the introduction of Gaussian noise perturbation to 20% of cells, both scGPT and SCMAMBA-2 saw an 11% decrease in accuracy while Geneformer saw an 8% decrease in accuracy. This difference in performance may be due to the difference in encoding methods used by both models. scGPT and SCMAMBA-2 use a bin-based tokenization strategy, in contrast to Geneformers rank-value encoding, which normalizes gene expression values using a predetermined encoding constant. Although binning captures general trends in count data, it fails to preserve relative expression at the gene level, resulting in significant information loss. Applying the three models to the Myeloid dataset also revealed that scGPTs prediction distribution is biased toward overrepresented cell types in the training data, while underrepresenting rarer classes. CD14 cells are overpredicted by 16% (among most abundant cell types) by scGPT. Geneformer, however, maintains a more stable prediction distribution with a 6% (CD14) increase and outperforms scGPT and SCMAMBA-2 by 26% in macro F1 score (unweighted metric). Based on our findings we assert that the gap in contextual encoding in bin-based tokenization is what contributes to the less-nuanced learning. Recent research that integrated cellular-ontology during training showed improved performance to both scGPT and Geneformer. Our results underscore a fundamental issue, that foundation models lack critical biological context that would allow for them to make the nuanced inferences required for complex biological analyses. The compression of single-cell data from raw counts to embedding vectors can span several orders of magnitude, and lead to significant loss of information. As a result, methods must adapt to prioritize contextual integration during tokenization to ensure sufficient information for the model.

bioinformatics↗

Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancer

BackgroundTriple-negative breast cancer is a prevalent breast cancer subtype with the lowest 5-year survival. Several factors contribute to its treatment response, but the inherent molecular and cellular tumor heterogeneity are increasingly acknowledged as crucial determinants. MethodsSpatial transcriptomic profiling was performed on FFPE tissues from a retrospective, treatment-naive group of women with differential prognoses (17 with >15 years survival-good prognosis (GPx) and 15 with <3 years survival-poor prognosis (PPx)) using GeoMX(R) Digital Spatial Profiler. Regions of interest were segmented on pan-cytokeratin and analyzed for tumor and stromal components, probed using GeoMx human whole transcriptome atlas (WTA) panel. Data quality control, normalization, and differential analysis was performed in R using GeomxTools and linear mixed models. Additional analyses including cell-type deconvolution, spatial entropy, functional enrichment, TF-target / ligand-receptor analysis and convolution neural networks were employed to identify significant gene signatures contributing to differential prognosis. ResultsHere we report on the spatial and molecular heterogeneity underlying differential prognosis. We observe that the state of the epithelia and its microenvironment (TME) are transcriptionally distinct between the two groups. Invasive epithelia in GPx show a significant increase in immune transcripts with the TME exhibiting increased immune cell presence (via IF), while in PPx they are more metabolically and translationally active, with the TME being more mesenchymal/fibrotic. Specifically, pre-cancerous epithelia in PPx display a prescience of aggressiveness as evidenced by increased EMT-signaling. We identify distinct epithelial gene signatures for PPx and GPx, that can, with high accuracy, classify samples at the time of diagnosis and likely inform therapy. ConclusionsTo the best of our knowledge, this is the first study to leverage spatial transcriptomics for an in-depth delineation of the cellular and molecular underpinnings of differential prognosis in TNBC. Our study highlights the potential of spatial transcriptomics to not only uncover the molecular drivers of differential prognosis in TNBC but also to pave the way for precision diagnostics and tailored therapeutic strategies, transforming the clinical landscape for this aggressive breast cancer subtype.

cancer biology↗